门静脉高压：危急重症交织于慢性多脏器功能衰竭

唐承薇

doi:10.3969/j.issn.1001-5256.2021.12.002

门静脉高压：危急重症交织于慢性多脏器功能衰竭

DOI: 10.3969/j.issn.1001-5256.2021.12.002

唐承薇^,

四川大学华西医院消化内科, 成都 610041

详细信息

通信作者:
唐承薇，shcqcdmed@163.com

中图分类号: R575.2
计量
- 文章访问数: 783
- HTML全文浏览量: 110
- PDF下载量: 154
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-21
- 录用日期: 2021-08-31
- 出版日期: 2021-12-20

Portal hypertension: Chronic multiple organ failure involving various critical severe diseases

Chengwei TANG^,

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China

摘要

摘要: 全球的肝硬化疾病负担很重，中国是全球肝硬化患者数量最多的国家。失代偿期肝硬化并发症如食管胃静脉曲张出血、自发性腹膜炎、肝性脑病及肝肾综合征等，常具备慢性多脏器功能不全的基础，这种慢加急性肝衰竭使患者生活质量差，危及生命。肝硬化门静脉高压既是肝硬化发展的后果，更是对肝硬化发展的二次打击甚至是叠加打击。有必要采用血管介入及研发新型药物早期降低肝内阻力，改善门静脉高压及患者预后。
- 高血压, 门静脉 /
- 肝硬化 /
- 慢加急性肝功能衰竭 /
- 门体分流术, 经颈静脉肝内
Abstract: Globally, the population living with liver cirrhosis is growing. There is the largest number of cirrhosis patients in China throughout the world. Acute-on-chronic liver failure (ACLF) is a clinical syndrome of sudden hepatic decompensations such as variceal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy and hepatorenal syndrome seen in patients with liver cirrhosis. ACLF leads to poor quality of life and high mortality. Portal hypertension is not only a consequence of the development of cirrhosis, but also a secondary or even superimposed attack to the development of cirrhosis. It is necessary to early reduce intrahepatic resistance by transjugular intrahepatic portosystemic shunt and drugs to improve the prognosis.
- Hypertension, Portal /
- Liver Cirrhosis /
- Acute-On-Chronic Liver Failure /
- Portasystemic Shunt, Transjugular Intrahepatic

HTML全文

参考文献(25)

[1]	LIU Z, JIANG Y, YUAN H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention[J]. J Hepatol, 2019, 70(4): 674-683. DOI: 10.1016/j.jhep.2018.12.001.
[2]	D'AMICO G, PASTA L, MORABITO A, et al. Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39(10): 1180-1193. DOI: 10.1111/apt.12721.
[3]	AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70(1): 9-29. DOI: 10.1136/gutjnl-2020-321790.
[4]	KUMAR R, MEHTA G, JALAN R. Acute-on-chronic liver failure[J]. Clin Med (Lond), 2020, 20(5): 501-504. DOI: 10.7861/clinmed.2020-0631.
[5]	TREBICKA J, GU W, IBÁÑEZ-SAMANIEGO L, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS[J]. J Hepatol, 2020, 73(5): 1082-1091. DOI: 10.1016/j.jhep.2020.04.024.
[6]	MANNING C, ELZUBEIR A, ALAM S. The role of pre-emptive transjugular intrahepatic portosystemic shunt in acute variceal bleeding: A literature review[J]. Ther Adv Chronic Dis, 2021, 12: 2040622321995771. DOI: 10.1177/2040622321995771.
[7]	GAO B, ZHUGE YZ. Malnutrition in liver cirrhosis: Benefits from improving portal hypertension[J]. J Clin Hepatol, 2021, 37(12): 2767-2769. DOI: 10.3969/j.issn.1001-5256.2021.12.005. 高波, 诸葛宇征. 肝硬化营养不良——从改善门静脉高压获益[J]. 临床肝胆病杂志, 2021, 37(12): 2767-2769. DOI: 10.3969/j.issn.1001-5256.2021.12.005.
[8]	QIAN SJ, WU H. Hepatic encephalopathy: Modern views on the treatment of abnormal portosystemic shunt[J]. J Clin Hepatol, 2021, 37(12): 2774-2777. DOI: 10.3969/j.issn.1001-5256.2021.12.007. 钱帅杰, 吴浩. 肝性脑病——异常门体分流处理的现代观[J]. 临床肝胆病杂志, 2021, 37(12): 2774-2777. DOI: 10.3969/j.issn.1001-5256.2021.12.007.
[9]	YANG LH, YANG JH. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. J Clin Hepatol, 2021, 37(12): 2770-2773. DOI: 10.3969/j.issn.1001-5256.2021.12.006. 杨黎宏, 杨晋辉. 肝肾综合征门体循环失衡的机制与治疗[J]. 临床肝胆病杂志, 2021, 37(12): 2770-2773. DOI: 10.3969/j.issn.1001-5256.2021.12.006.
[10]	HORHAT A, BUREAU C, THABUT D, et al. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020[J]. United European Gastroenterol J, 2021, 9(2): 203-208. DOI: 10.1177/2050640620952637.
[11]	de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[12]	TRIPATHI D, STANLEY AJ, HAYES PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11): 1680-1704. DOI: 10.1136/gutjnl-2015-309262.
[13]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
[14]	European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[15]	RÖSSLE M, SIEGERSTETTER V, OLSCHEWSKI M, et al. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts[J]. Am J Gastroenterol, 2001, 96(12): 3379-3383. DOI: 10.1111/j.1572-0241.2001.05340.x.
[16]	CHEN S, LI X, WEI B, et al. Recurrent variceal bleeding and shunt patency: Prospective randomized controlled trial of transjugular intrahepatic portosystemic shunt alone or combined with coronary vein embolization[J]. Radiology, 2013, 268(3): 900-906. DOI: 10.1148/radiol.13120800.
[17]	LI Z, ZHANG CQ. Esophageal and gastric variceal bleeding in liver cirrhosis: Embolization or shunt[J]. J Clin Hepatol, 2021, 37(12): 2764-2766. DOI: 10.3969/j.issn.1001-5256.2021.12.004. 李振, 张春清. 肝硬化食管胃静脉曲张出血: 堵抑或疏?[J]. 临床肝胆病杂志, 2021, 37(12): 2764-2766. DOI: 10.3969/j.issn.1001-5256.2021.12.004.
[18]	GAO JH, WEN SL, TONG H, et al. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(11): g962-g972. DOI: 10.1152/ajpgi.00428.2015.
[19]	WEN SL, GAO JH, YANG WJ, et al. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes[J]. J Gastroenterol Hepatol, 2014, 29(11): 1932-1942. DOI: 10.1111/jgh.12641.
[20]	BRUSILOVSKAYA K, KÖNIGSHOFER P, SCHWABL P, et al. Vascular targets for the treatment of portal hypertension[J]. Semin Liver Dis, 2019, 39(4): 483-501. DOI: 10.1055/s-0039-1693115.
[21]	TSOCHATZIS EA, SENZOLO M, GERMANI G, et al. Systematic review: Portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther, 2010, 31(3): 366-374. DOI: 10.1111/j.1365-2036.2009.04182.x.
[22]	ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. DOI: 10.1016/j.jhep.2020.11.048.
[23]	INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599. e1. DOI: 10.1053/j.gastro.2019.01.265.
[24]	BOIKE JR, FLAMM SL. Transjugular intrahepatic portosystemic shunts: Advances and new uses in patients with chronic liver disease[J]. Clin Liver Dis, 2020, 24(3): 373-388. DOI: 10.1016/j.cld.2020.04.007.
[25]	TRANAH TH, EDWARDS LA, SCHNABL B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70(5): 982-994. DOI: 10.1136/gutjnl-2020-320786.